Ryo Mukai, Keiko Kataoka, Koji Tanaka, Yasunori Miyara, Ichiro Maruko, Makiko Nakayama, Yuto Watanabe, Akiko Yamamoto, Yu Wakatsuki, Hajime Onoe, Sorako Wakugawa, Nobuhiro Terao, Taiji Hasegawa, Moeko Kawai, Ruka Maruko, Kanako Itagaki, Jyunichiro Honjo, Annabelle A Okada, Ryusaburo Mori, Hideki Koizumi, Tomohiro Iida, Tetsuju Sekiryu
This multicentre retrospective study evaluated the 1-year outcomes and safety profile of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Fifty-five patients (57 eyes) underwent loading therapy comprising three monthly faricimab injections. If dryness was achieved by the third month, subsequent treat-and-extend (TAE) follow-up continued at a minimum 8-week interval thereafter. If wet macula persisted at the third month, a fourth dose was administered, followed by the TAE regimen...
May 22, 2024: Scientific Reports